Vitamin D status and breast cancer risk

Anticancer Research

Volumn 26, Issue 4 A, 2006, Pages 2573-2580

  Colston, Kay W ^a   Lowe, Lorraine C ^a   Mansi, Janine L ^a   Campbell, Moray J ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

1 ,25 dihydroxyvitamin D3; Breast cancer; CYP24; CYP27b1; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; CYTOCHROME P450; ENZYME; MESSENGER RNA; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER MODEL; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; BREAST NEOPLASMS; CALCIFEDIOL; CALCITRIOL; CASE-CONTROL STUDIES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; RISK FACTORS; STEROID HYDROXYLASES;

EID: 33746599562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Agadir A, Lazzaro G, Zheng Y, Zhang XK and Mehta R: Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis 20: 577-582, 1999.
2. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25: 144-146, 2000.
3. Anderson DE: Breast cancer in families. Cancer 40: 1855-1860, 1977.
4. Anderson DE and Badzioch M: Risk of familial breast cancer. Lancet 1: 392, 1984.
5. 3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J Steroid Biochem Mol Biol 89-90: 245-249, 2004.
6. Bischof MG, Siu-Caldera ML, Weiskopf A, Vouros P, Cross HS, Peterlik M and Reddy GS: Differentiation-related pathways of 1 alpha,25- dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1 alpha,25-dihydroxy-3epicholecalciferol. Exp Cell Res 241: 194-201, 1998.
7. 3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 52: 985-989, 2004.
8. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA and Strange RC: Polymorphisms in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer. Environ Mol Mutagen 43: 121-127, 2004.
9. 3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19: 5091-5097, 2000.
10. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66: 413-425, 1997.
11. Chesney RW, Rosen JF, Hamstra AJ, Smith C, Mahaffey K and DeLuca HF: Absence of seasonal variation in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J Clin Endocrinol Metab 53: 139-142, 1981.
12. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH and Rosner BA: Family history, age and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 270: 338-343, 1993.
13. Colston KW: New concepts in hormone receptor action. Lancet 342: 67-68, 1993.
14. Colston KW, Berger U and Coombes RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1: 188-191, 1989.
15. 3 - relevance for colonic cancer prevention and therapy. Mol Aspects Med 24: 459-465, 2003.
16. Cross HS, Kallay E, Lechner D, Gerdenitsch W, Adlercreutz H and Armbrecht HJ: Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate and mammary carcinomas. J Nutr 134: 1207S-1212S, 2004.
17. 3 metabolism in human glioblastoma multiforme: Functionality of CYP27B1 splice variants, metabolism of calcidiol and effect of calcitriol. Clin Cancer Res 11: 5370-5380, 2005.
18. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995.
19. Evans KN, Taylor H, Zehnder D, Kilby MD, Bulmer JN, Shah F, Adams JS and Hewison M: Increased expression of 25-hydroxyvitamin D-1alphahydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 165: 807-813, 2004.
20. Friedrich M: Vitamin D and breast cancer: new approaches for hormonal therapy of breast cancer. Clin Exp Obstet Gynecol 27: 77-82, 2000.
21. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W and Reichrath J: Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J 34: 35-40, 2002.
22. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W and Reichrath J: Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Rec Results Cancer Res 164: 239-246, 2003.
23. 3-1alpha- hydroxylase in cervical tissue. Anticancer Res 22: 183-186, 2002.
24. Garland CF and Garland FC: Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 9: 227-231, 1980.
25. Garland FC, Garland CF, Gorham ED and Young JF: Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19: 614-622, 1990.
26. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL and Colston KW: Approaches to evaluating the association of vitamin D receptor gene polymorphisms with breast cancer risk. Rec Results Cancer Res 164: 43-54, 2003.
27. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, Wilson RG, Thomas V and Colston KW: Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res 10: 5472-5481, 2004.
28. Henderson MM: Nutritional aspects of breast cancer. Cancer 76: 2053-2058, 1995.
29. 3-induced growth inhibition. Cancer Res 61: 2852-2856, 2001.
30. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW and Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170, 1997.
31. James SY, Mackay AG and Colston KW: Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 14: 391-394, 1995.
32. Jensen SS, Madsen MW, Lukas J, Bartek J and Binderup L: Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with vitamin D receptor protein induction. J Steroid Biochem Mol Biol 81: 123-133, 2002.
33. John EM, Schwartz GG, Koo J, Van Den BD and Ingles SA: Sun exposure, vitamin D receptor gene polymorphisms and risk of advanced prostate cancer. Cancer Res 65: 5470-5479, 2005.
34. Jones G, Ramshaw H, Zhang A, Cook R, Byford V, White J and Petkovich M: Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 140: 3303-3310, 1999.
35. Kallay E, Bises G, Bajna E, Bieglmayer C, Gerdenitsch W, Steffan I, Kato S, Armbrecht HJ and Cross HS: Colon-specific regulation of vitamin D hydroxylases - a possible approach for tumor prevention. Carcinogenesis 26: 1581-1589, 2005.
36. Krishnan AV, Peehl DM and Feldman D: The role of vitamin D in prostate cancer. Rec Results Cancer Res 164: 205-221, 2003.
37. 3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast and hematopoietic cancer cells. Cancer Res 58: 3370-3375, 1998.
38. 3 and EB1089 on cell growth and Vitamin D receptor mRNA and 1alpha-hydroxylase mRNA expression in primary cultures of the canine prostate. J Steroid Biochem Mol Biol 89-90: 409-412, 2004.
39. Lechner D and Cross HS: Phytoestrogens and 17beta-estradiol influence vitamin D metabolism and receptor expression-relevance for colon cancer prevention. Rec Results Cancer Res 164: 379-391, 2003.
40. Lipkin M and Newmark HL: Vitamin D, calcium and prevention of breast cancer: a review. J Am Coll Nutr 18: 392S-397S, 1999.
41. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG and Colston KW: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41: 1164-1169, 2005.
42. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH and Hunter DJ: Vitamin D receptor polymorphisms, circulating vitamin D metabolites and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7: 385-390, 1998.
43. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D and Peehl DM: Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol 221: 67-74, 2004.
44. Matusiak D, Murillo G, Carroll RE, Mehta RG and Benya RV: Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14: 2370-2376, 2005.
45. 3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology 138: 4690-4698, 1997.
46. Narvaez CJ, Zinser G and Welsh J: Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 66: 301-308, 2001.
47. Prosser DE and Jones G: Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29: 664-673, 2004.
48. Schwartz GG: Vitamin D and the epidemiology of prostate cancer. Semin Dial 18: 276-289, 2005.
49. 3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7: 391-395, 1998.
50. 3 1alpha-hydroxylase and vitamin D synthesis. Science 277: 1827-1830, 1997.
51. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ and Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11: 3579-3586, 2005.
52. 3 receptor null mice. Mol Endocrinol 18(9): 2208-2223, 2004.
53. Welsh J: Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 80: 1721S-1724S, 2004.
54. Yokomura K, Suda T, Sasaki S, Inui N, Chida K and Nakamura H: Increased expression of the 25-hydroxyvitamin D(3)-1alpha-hydroxylase gene in alveolar macrophages of patients with lung cancer. J Clin Endocrinol Metab 88: 5704-5709, 2003.
55. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM and Hewison M: Extrarenal expression of 25-hydroxyvitamin D(3)-1 alphahydroxylase. J Clin Endocrinol Metab 86: 888-894, 2001.
56. Zinser G, Packman K and Welsh J: Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 129: 3067-3076, 2002.
57. Zinser GM and Welsh J: Effect of Vitamin D(3) receptor ablation on murine mammary gland development and tumorigenesis. J Steroid Biochem Mol Biol 89-90: 433-436, 2004.
58. Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS and Hewison M: Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 97(1-2): 103-109, 2005.